2 news items
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
ABVC
AMGN
CADL
15 May 24
are collaborating on CX-904, a bispecific PROBODY candidate designed to engage T-cells by targeting the epidermal growth factor receptor (EGFR
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
ABVC
AMGN
CADL
15 May 24
are collaborating on CX-904, a bispecific PROBODY candidate designed to engage T-cells by targeting the epidermal growth factor receptor (EGFR) on cancer cells
- Prev
- 1
- Next